Navigation Links
China-Biotics Attended National Probiotics Seminar
Date:12/7/2010

SHANGHAI, Dec. 7, 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: CHBT) the leading developer, manufacturer and distributor of probiotics products in China, today announced that a delegation from the Company's research and development department presented at the National Probiotics Research and Development, New Application and Equipment seminar in Hangzhou, China on November 21st.

The seminar was organized and hosted by the National High-Tech Industrialization Association. More than 180 research and development professionals from global industry leaders and other probiotics companies participated in the event.

The Company's R&D specialists presented on bifidobacterium infantis, focusing on the fermentation techniques, quality assurance on product stability, and the application of bifidobacterium infantis in health food products.

Mr. Jinan Song, Chairman and CEO of China-Biotics, commented, "Research and development and the application of probiotics is accelerating in China as consumers continue to grasp the beneficial effects of probiotics. Meanwhile, the Chinese government is also poised to implement stricter enforcement to reduce the use of antibiotics use in animal feed. As a result, the probiotics industry is experiencing linear growth with rising popularity among consumers and favorable policy supports. Advancement in production techniques and the gradual standardization of industry practices have laid the foundation for more dairy and animal producers to embrace probiotics."

About China-BioticsChina-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com.

Safe Harbor Statement The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward- looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.Contact:Travis Cai Chief Financial OfficerChina-Biotics, Inc.traviscai@chn-biotics.comShiwei Yin/Dixon Chen Grayling646-284-9474shiwei.yin@grayling.comdixon.chen@grayling.com
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics to Attend BNP Paribas China Conference
2. China-Biotics to Present at Jefferies Healthcare Conference
3. China-Biotics Files New Patent Applications
4. China-Biotics, Inc. Comments on Market Rumors
5. China-Biotics Announces September 20 Investor Day Schedule
6. China-Biotics to Host Investor Day in Shanghai to Discuss Corporate Development Strategy
7. China-Biotics, Inc. Announces US$20 million Share Buyback Program
8. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
9. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Nueterra, ... formerly specialized in the development of equity ... that it has divided its interests between ... Nueterra Capital will continue the founding company,s ... will operate a national system of integrated ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint Solutions ... Group (NRG),s pharmacovigilance technology services division.  NRG ... services and an Oracle Argus Specialized partner, providing ... Life Sciences companies. --> ... HighPoint,s life sciences capabilities and provides a global ...
(Date:2/8/2016)... --  Intarcia Therapeutics, Inc. today announced the appointment ... newly created role of Vice President, Head of Global ... decades of leadership experience at leading pharmaceutical, biotechnology, and ... center. Most recently Dr. Yee served as VP, Head ... Medical Officer at AstraZeneca, where he led medical affairs ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
Breaking Medicine News(10 mins):